Takeda Pharmaceutical Co Ltd
TSE:4502
Takeda Pharmaceutical Co Ltd
TSE:4502
Price:
4 125 JPY
-0.43%
Updated:
May 2, 2024
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT
22.5
Current
21.1
Median
17
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
EV/EBIT
=22.5
Enterprise Value
/
10.4T
EBIT
464.9B
All Countries
| Market Cap | EV/EBIT | ||||
|---|---|---|---|---|---|
| JP |
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
6.5T JPY | 22.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737.4B USD | 72.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 38 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 17 702.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 4 320.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
363.9B USD | 15.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
326.1B USD | 53.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.8B GBP | 225.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
181.8B CHF | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
174.4B CHF | 10.3 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBIT
0
2-Years Forward
EV/EBIT
10.5
3-Years Forward
EV/EBIT
N/A
You don't have any saved screeners yet
